EcoDrugPlus

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSOPRG00000009049
Gene Symbol: CHRM3
3 Cross references
255 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSOPRG00000002062
Gene Symbol: CHRNA3
1 Cross references
207 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 4 Subunit

Ensembl ID : ENSOPRG00000005933
Gene Symbol: CHRNA4
3 Cross references
204 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 7 Subunit

Ensembl ID : ENSOPRG00000017241
Gene Symbol: CHRNA7
1 Cross references
243 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSOPRG00000000309
Gene Symbol: CHRNB2
3 Cross references
197 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSOPRG00000002077
Gene Symbol: CHRNB4
1 Cross references
198 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSOPRG00000009364
Gene Symbol: F2R
3 Cross references
327 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSOPRG00000004800
Gene Symbol: F3
1 Cross references
243 Possible Orthologues:

Coagulation Factor Vii

Ensembl ID : ENSOPRG00000015989
Gene Symbol: F7
3 Cross references
274 Possible Orthologues:

Coagulation Factor Xi

Ensembl ID : ENSOPRG00000005205
Gene Symbol: F11
1 Cross references
216 Possible Orthologues:

Coagulation Factor Xii

Ensembl ID : ENSOPRG00000002694
Gene Symbol: F12
1 Cross references
185 Possible Orthologues:

Coiled-Coil Domain Containing 6

Ensembl ID : ENSOPRG00000014790
Gene Symbol: CCDC6
1 Cross references
219 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).